Cited by 112Sirtuins and Resveratrol in MedicineMetabolism, Diabetes, and CancerNatural Antidiabetic Agents Studies

Resveratrol-Induced AMP-Activated Protein Kinase Activation Is Cell-Type Dependent: Lessons from Basic Research for Clinical Application

Open access
Lan, Fan, Weikel, Karen, Cacicedo, Jose, Ido, Yasuo·2017·Nutrients

Abstract

Despite the promising effects of resveratrol, its efficacy in the clinic remains controversial. We were the first group to report that the SIRT1 activator resveratrol activates AMP-activated protein kinase (AMPK) (Diabetes 2005; 54: A383), and we think that the variability of this cascade may be responsible for the inconsistency of resveratrol’s effects. Our current studies suggest that the effect of SIRT1 activators such as resveratrol may not be solely through activation of SIRT1, but also through an integrated effect of SIRT1-liver kinase B1 (LKB1)-AMPK. In this context, resveratrol activates SIRT1 (1) by directly binding to SIRT1; and (2) by increasing NAD+ levels by upregulating the salvage pathway through Nampt activation, an effect mediated by AMPK. The first mechanism promotes deacetylation of a limited number of SIRT1 substrate proteins (e.g., PGC-1). The second mechanism (which may be more important than the first) activates other sirtuins in addition to SIRT1, which affects a broad spectrum of substrates. Despite these findings, detailed mechanisms of how resveratrol activates AMPK have not been reported. Here, we show that (1) resveratrol-induced activation of AMPK requires the presence of functional LKB1; (2) Resveratrol increases LKB1 activity, which involves translocation and phosphorylation at T336 and S428; (3) Activation of LKB1 causes proteasomal degradation of LKB1; (4) At high concentrations (50–100 µM), resveratrol also activates AMPK through increasing AMP levels; and (5) The above-mentioned activation mechanisms vary among cell types, and in some cell types, resveratrol fails to activate AMPK. These results suggest that resveratrol-induced activation of AMPK is not a ubiquitous phenomenon. In addition, AMPK-mediated increases in NAD+ in the second mechanism require several ATPs, which may not be available in many pathological conditions. These phenomena may explain why resveratrol is not always consistently beneficial in a clinical setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu9070751

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 49 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Lan, F., Weikel, K., Cacicedo, J., & Ido, Y.
Affiliations
  • First People's Hospital of Chongqing (CN)
  • Boston University (US)
  • Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Corresponding author
Ido, Yasuo
Venue
Nutrients
Publisher
MDPI AG
Published
2017-07-14
Volume
9
Issue
7
Pages
751
ISSN
2072-6643 (ISSN-L)
OpenAlex
W2734616255
Cited by
112
References
49
Citations by year
2026: 8 · 2025: 14 · 2024: 11 · 2023: 7 · 2022: 13 · 2021: 17 · 2020: 19 · 2019: 11 · 2018: 10 · 2017: 2
FWCI
6.94
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • BU bridge fund (None)
  • NIH (HL068758)
  • Kilo diabetes & Vascular (None)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
Keywords
resveratrol, AMPK, SIRT1, LKB1, NAD+ salvage pathway, visfatin, sirtuins, PGC-1, proteasomal degradation
MeSH terms
Resveratrol, AMP-Activated Protein Kinase Kinases, Animals, Cricetulus, Enzyme Activation, HeLa Cells, Humans, Phosphorylation, Stilbenes, CHO Cells, Protein Serine-Threonine Kinases, Sirtuins, 3T3-L1 Cells, Proteasome Endopeptidase Complex, Mice, AMP-Activated Protein Kinases, Sirtuin 1, HEK293 Cells, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review